المؤلفون: Drew W. Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil I. Daud, Jiaheng Qiu, Viviana Bozon, Michelle Kneissl, Elly Barry, Anthony J. Olszanski

المساهمون: Barry, Elly [0000-0002-6890-2444], Apollo - University of Cambridge Repository

المصدر: Cancer chemotherapy and pharmacology, vol 92, iss 1

مصطلحات موضوعية: Adult, Proto-Oncogene Proteins B-raf, Cancer Research, Skin Neoplasms, Maximum Tolerated Dose, Clinical Trials and Supportive Activities, Phase 1, Toxicology, BRAF, Clinical Research, Neoplasms, Humans, Pharmacology (medical), Oncology & Carcinogenesis, Melanoma, Protein Kinase Inhibitors, Pan-RAF inhibitor, Cancer, Pharmacology, Mitogen-Activated Protein Kinase Kinases, Evaluation of treatments and therapeutic interventions, Neoplasms, Second Primary, Pharmacology and Pharmaceutical Sciences, Second Primary, Oncology, 6.1 Pharmaceuticals, Tovorafenib

وصف الملف: application/pdf; application/zip; text/xml

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be879ecf897194f5e93f0a32cbcfa4dTest
https://www.repository.cam.ac.uk/handle/1810/350906Test

المؤلفون: C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous

المساهمون: Surgery, Faculty of Medicine and Pharmacy, Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON)

المصدر: European Journal of Cancer, 151, 72-83. Elsevier Ltd.
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003Test
European Journal of Cancer, 151, 72-83. ELSEVIER

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Systemic therapy, 0302 clinical medicine, Stable Disease, Risk Factors, METASTATIC MELANOMA, Immune Checkpoint Inhibitors, Melanoma, OUTCOMES, Manchester Cancer Research Centre, Progression-free survival, Radiotherapy Dosage, Middle Aged, Progression-Free Survival, Europe, 030220 oncology & carcinogenesis, Disease Progression, SURVIVAL, Female, Immune checkpoint inhibition, medicine.symptom, medicine.medical_specialty, Oligoprogression, Metastatic melanoma, Lesion, Solitary progression, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, IMMUNOTHERAPY, Aged, Neoplasm Staging, Retrospective Studies, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Australia, Metastasectomy, Immunotherapy, medicine.disease, United States, Immune checkpoint, Treatment, METASTASES, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5670859b7c5acf15c6f3031b69510901Test
https://doi.org/10.1016/j.ejca.2021.04.003Test

المؤلفون: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf

المساهمون: University of Zurich

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601Test

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Adult, Cancer Research, Skin Neoplasms, Adolescent, Pyridones, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Medizin, 610 Medicine & health, Pyrimidinones, Antibodies, Death Domain, Clinical Research, Neoplasms, Oximes, Antineoplastic Combined Chemotherapy Protocols, Receptors, Monoclonal, Genetics, Humans, Oncology & Carcinogenesis, Melanoma, Humanized, Cancer, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Human Genome, Imidazoles, Evaluation of treatments and therapeutic interventions, 10177 Dermatology Clinic, Second Primary, Oncology, 6.1 Pharmaceuticals, Mutation

وصف الملف: 928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdf - application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512e67c5f66bacf61087d7e838e0dc59Test
https://www.zora.uzh.ch/id/eprint/213526Test/

المؤلفون: Oliver J. Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna M. Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

المصدر: European Journal of Cancer, 165, 97-112
European Journal of Cancer, 165, pp. 97-112
Kennedy, O J, Kicinski, M, Valpione, S, Gandini, S, Suciu, S, Blank, C U, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, van Akkooi, A C J, Robert, C, Eggermont, A M M, Lorigan, P & Mandala, M 2022, ' Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 165, pp. 97-112 . https://doi.org/10.1016/j.ejca.2022.01.017Test

مصطلحات موضوعية: Cancer Research, Skin Neoplasms, Adrenergic beta-Antagonists, Medizin, Antibodies, Monoclonal, Humanized, Adrenergic beta-antagonists, Beta-blockers, Immunomodulation, Immunotherapy, Melanoma, Adjuvants, Immunologic, Humans, Neoplasm Staging, Prognosis, Tumor Microenvironment, Antibodies, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], All institutes and research themes of the Radboud University Medical Center, Immunologic, Monoclonal, Adjuvants, Humanized, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Oncology

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75ba607dbd7225632c8df9aab98b7d3Test
http://hdl.handle.net/2066/250190Test

المؤلفون: Kristina V. Orlova, Mahtab Samimi, Paul Lorigan, Elena Benincasa, Nicola Fazio, Eyal Fenig, Vanna Chiarion Sileni, Paolo A. Ascierto, Nora Kramkimel, Ana Arance, Nuno Costa, Monika Dudzisz-Śledź, Oliver Bechter, Laurent Mortier, Giovanni Grignani, Lenka Kostkova, Christoffer Gebhardt, Neil Steven

المصدر: Ascierto, P A, Orlova, K, Grignani, G, Dudzisz-Sledz, M, Fenig, E, Sileni, V C, Fazio, N, Samimi, M, Mortier, L, Gebhardt, C, Kramkimel, N, Steven, N, Bechter, O, Arance, A, Benincasa, E, Kostkova, L, Costa, N & Lorigan, P 2021, ' Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East ', International Journal of Cancer, vol. 149, no. 11, pp. 1926-1934 . https://doi.org/10.1002/ijc.33746Test

مصطلحات موضوعية: Adult, Compassionate Use Trials, Male, PD-L1, second-line, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Aggressive disease, Antibodies, Monoclonal, Humanized, Avelumab, Middle East, Antineoplastic Agents, Immunological, Merkel cell carcinoma, Internal medicine, medicine, Humans, In patient, Adverse effect, Objective response, Aged, Aged, 80 and over, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Middle Aged, medicine.disease, Carcinoma, Merkel Cell, Europe, Treatment Outcome, Oncology, expanded access program, Expanded access, Female, avelumab, Skin cancer, business, medicine.drug

وصف الملف: Print-Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d499a483301678f51b0eddc287ad25Test
https://doi.org/10.1002/ijc.33746Test

المؤلفون: Nathalie Dhomen, Elena Galvani, Luca Giovanni Campana, Sara Valpione, Sarah Mills, John Weightman, Paul Lorigan, Avinash Gupta, Piyushkumar A. Mundra, Richard Marais, Francesco De Rosa

المصدر: Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Nature Communications

مصطلحات موضوعية: Adult, Male, Skin Neoplasms, Statistical methods, Biopsy, T-Lymphocytes, Science, medicine.medical_treatment, Receptors, Antigen, T-Cell, General Physics and Astronomy, Cancer immunotherapy, Predictive markers, General Biochemistry, Genetics and Molecular Biology, Cohort Studies, Lymphocytes, Tumor-Infiltrating, Biomarkers, Tumor, Humans, Medicine, Author Correction, Melanoma, Aged, Aged, 80 and over, Multidisciplinary, business.industry, Cancer survival, General Chemistry, Middle Aged, Prognosis, T-Cell Receptor Repertoire, Survival Rate, Cancer research, Tumour immunology, Female, Immunotherapy, business, Tumor immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05bd13cf857ce5a417a77188e7d48871Test
https://doi.org/10.1038/s41467-021-24897-wTest

المؤلفون: Thomas Eigentler, Cindy Franklin, Anja Gesierich, Claus Garbe, Sebastian Haferkamp, James Larkin, Sophia Kreft, Paul Lorigan, Bastian Schilling, Sara Valpione, Selma Ugurel, Jochen Utikal, Dirk Schadendorf, Christian U. Blank

المصدر: European Journal of Cancer. 116:207-215

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Adverse effect, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Salvage Therapy, business.industry, Immunotherapy, Middle Aged, medicine.disease, Confidence interval, Nivolumab, Treatment Outcome, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f33bef3ecdaf233f4184cbdb0bbc1eTest
https://doi.org/10.1016/j.ejca.2019.05.015Test

المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

المؤلفون: Elena Galvani, Garima Khandelwal, Paul Lorigan, Richard Marais, Franziska Baenke, Rebecca Lee, Kenneth G. MacLeod, Amaya Viros, Piyushkumar A. Mundra, Alessio Cannistraci, Matthew Smith, Crispin J. Miller, Neil O. Carragher, Nathalie Dhomen, Gabriela Gremel, Garry Ashton, A. Mandal

المصدر: Lee, R, Khandelwal, G, Baenke, F, Cannistraci, A, McCleod, K, Mundra, P, Ashton, G, Mandal, A, Viros, A, Gremel, G, Galvani, E, Smith, M, Carragher, N, Dhoumen, N, Miller, C, Lorigan, P & Marais, R 2020, ' Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma ', ESMO Open . https://doi.org/10.1136/esmoopen-2020-000707Test
ESMO Open
Lee, R J, Khandelwal, G, Baenke, F, Caccistraci, A, Macleod, K, Mundra, P, Ashton, G, Mandal, A, Viros, A, Gremel, G, Galvani, E, Smith, M, Carragher, N, Dhomen, N, Miller, C J, Lorigan, P & Marais, R 2020, ' Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma ', ESMO Open . https://doi.org/10.1136/esmoopen-2020-000707Test

مصطلحات موضوعية: Cancer Research, Skin Neoplasms, medicine.medical_treatment, Cell, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Immune system, Downregulation and upregulation, immune therapy, medicine, Tumor Microenvironment, Humans, brain metastasis, Molecular Targeted Therapy, Melanoma, 030304 developmental biology, Original Research, 0303 health sciences, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Brain, Dabrafenib, medicine.disease, targeted therapy, 3. Good health, acral melanoma, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Cancer research, Immunotherapy, Nivolumab, business, Brain metastasis, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45dba314e22aacdffbfdc248559483cfTest
https://research.manchester.ac.uk/en/publications/f7e33f48-38a2-4494-b298-d8ef3c6ed4a1Test

المؤلفون: Viktoria Chatzimavridou-Grigoriadou, Claire E Higham, Paul Lorigan, Cheryl T. Fitzgerald, Peter J Trainer, Alexander M.M. Eggermont

المصدر: Higham, C E, Chatzimavridou-Grigoriadou, V, Fitzgerald, C T, Trainer, P J, Eggermont, A M M & Lorigan, P 2020, ' Adjuvant immunotherapy : the sting in the tail ', European Journal of Cancer, vol. 132, pp. 207-210 . https://doi.org/10.1016/j.ejca.2020.03.016Test

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions, Diabetic ketoacidosis, Levothyroxine, Lower risk, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Adjuvants, Immunologic, Internal medicine, Diabetes mellitus, medicine, Adjuvant therapy, Humans, Melanoma, Depression (differential diagnoses), Cancer staging, Adjuvant immunotherapy, Manchester Cancer Research Centre, business.industry, Endocrine toxicity, Late effects, ResearchInstitutes_Networks_Beacons/mcrc, Absolute risk reduction, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, Fertility, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Immunotherapy, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5cfc6ad40e841b8a213223876f0298Test
https://research.manchester.ac.uk/en/publications/4a38829b-1fce-4872-b777-a702ca6197feTest